Filtered By:
Specialty: Hematology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 643 results found since Jan 2013.
Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention
Platelets. 2021 Apr 4:1-8. doi: 10.1080/09537104.2021.1909717. Online ahead of print.ABSTRACTIt remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in Chinese patients with ACS undergoing percutaneous coronary intervention (PCI). In this observational cohort study, a total of 2110 ACS patients who were event-free at 3 months after the index PCI were divided into standard-dose ticagrelor (90 mg twice daily) (n = 1830) or low-dose ticagre...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Yue Wang Beibei Liu Leilei Chen Yue Wang Zhiqiang Wang Xiaojiang Zhang Min Suo Gary S Mintz Xiaofan Wu Source Type: research
Impact of Transcatheter Aortic Valve Implantation on Thrombin Generation and Platelet Function
CONCLUSION: In this pilot study, we were able to demonstrate that thrombin generation is significantly increased early after TAVI, while platelet function is not affected. Increased thrombin concentrations may contribute to the high risk of postprocedural thromboembolic events. This leads to the hypothesis that extended peri-interventional anticoagulation early after TAVI may be an approach to reduce thromboembolic events.PMID:33759144 | DOI:10.1055/s-0041-1725190
Source: Thrombosis and Haemostasis - March 24, 2021 Category: Hematology Authors: Philipp Mourikis Lisa Dannenberg Saif Zako Carolin Helten Ren é M'Pembele Hannah Richter Thomas Hohlfeld Christian Jung Tobias Zeus Malte Kelm Verena Veulemans Amin Polzin Source Type: research
The outcomes of three-factor prothrombin complex concentrate (3F-PCC) in warfarin anticoagulation reversal: a prospective, single-arm, open-label, multicentre study
AbstractThere is a wide variation on the efficacy of three-factor Prothrombin Complex Concentrate (3F-PCC) in warfarin reversal. We aimed to determine the efficacy and safety of 3F-PCC in warfarin reversal. This multicentre prospective study analysed data from adult patients on warfarin who received 3F-PCC (Prothrombinex-VF ®) for anticoagulation reversal between June 2019 to October 2020. Purposive sampling was used in this study. Study endpoints included target INR achievement, adverse drug reactions (ADRs), and in-hospital all-cause mortality. Logistic regression analyses were used to assess independent predictors of s...
Source: Journal of Thrombosis and Thrombolysis - March 21, 2021 Category: Hematology Source Type: research
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis
AbstractTo evaluate major bleeding in cirrhosis with use of traditional anticoagulation or direct oral anticoagulants (DOACs), using a standardized definition. Anticoagulation in patients with cirrhosis is often a clinical conundrum for providers as the necessary balance between thrombotic and bleeding risk is complicated by end organ damage. Recent meta-analyses have sought to evaluate the safety and efficacy of direct oral anticoagulants in patients with liver disease. These recent analyses are limited by various bleeding definitions, broad inclusion criteria, and few indications for anticoagulation. We sought to conduct...
Source: Journal of Thrombosis and Thrombolysis - March 16, 2021 Category: Hematology Source Type: research
Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure
AbstractUp to now we have had few evidences on the Non-vitamin K Antagonist Oral Anticoagulants (NOACs) ’ efficacy and safety in preventing device-related thrombosis (DRT) after percutaneous left atrial appendage closure (LAAC). After LAAC implantation, short-term anticoagulation (NOACs or warfarin) was prescribed. Baseline clinical characteristics, procedural parameters and postoperative follow up data were collected and compared between the two groups. From May 2014 to June 2018, 361 consecutive patients underwent LAAC implantation in our center. 170 patients received warfarin for 45 days at least after LAAC implantat...
Source: Journal of Thrombosis and Thrombolysis - March 5, 2021 Category: Hematology Source Type: research
Structure-function relationship of the platelet glycoprotein VI (GPVI) receptor: does it matter if it is a dimer or monomer?
Platelets. 2021 Feb 26:1-8. doi: 10.1080/09537104.2021.1887469. Online ahead of print.ABSTRACTGPVI is a critical signaling receptor responsible for collagen-induced platelet activation and a promising anti-thrombotic target in conditions such as coronary artery thrombosis, ischemic stroke, and atherothrombosis. This is due to the ability to block GPVI while having minimal effects on hemostasis, making it a more attractive target over current dual-antiplatelet therapy (DAPT) with acetyl salicylic acid and P2Y12 inhibitors where bleeding can be a problem. Our current understanding of how the structure of GPVI relates to func...
Source: Platelets - February 26, 2021 Category: Hematology Authors: Joanne C Clark Foteini-Nafsika Damaskinaki Yam Fung Hilaire Cheung Alexandre Slater Steve P Watson Source Type: research
Direct Oral Anticoagulants Plasma Levels Measurement: Clinical Usefulness from Trials and Real-World Data
Semin Thromb Hemost 2021; 47: 150-160 DOI: 10.1055/s-0041-1723770Measurement of direct oral anticoagulants (DOACs) activity is not routinely necessary. Indeed, evaluation of DOACs plasmatic concentration is discouraged for the majority of patients, due to the lack of outcome data supporting this approach. Nevertheless, DOAC measurements may be useful in emergency situations such as serious bleeding events, need for urgent invasive procedures, and acute ischemic stroke or in managing anticoagulation in “special populations” not adequately studied in clinical trials, for example the very elderly or those at the extremes ...
Source: Seminars in Thrombosis and Hemostasis - February 26, 2021 Category: Hematology Authors: Renon, Francesca Rago, Anna Liccardo, Biagio D'Andrea, Antonello Riegler, Lucia Golino, Paolo Nigro, Gerardo Russo, Vincenzo Tags: Review Article Source Type: research
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease
Discussion. OFXais were better tolerated compared to warfarin for the treatment of VTE in CKD, with lower rates of bleeding, discontinuations, and recurrent thromboembolism in a small cohort. Future prospective studies are necessary to confirm these findings.PMID:33628255 | PMC:PMC7895609 | DOI:10.1155/2021/8870015
Source: Advances in Hematology - February 25, 2021 Category: Hematology Authors: Tania Ahuja Kelly Sessa Cristian Merchan John Papadopoulos David Green Source Type: research
